What changed in this filing

/stocks — the workspaceLOADING

Item 1. Legal Proceedings

2021-08-05 compared with 2021-05-06 · 54 added, 43 removed, 6 unchanged (94% of the section changed)

LEGAL PROCEEDINGS

April 2, 2019, we filed a lawsuit against Clarus in the United States District Court for the District of Delaware alleging

that Clarus’s JATENZO®

product infringes six of Lipocine’s issued U.S.

and 6,923,988.

April 2, 2019, we filed a lawsuit against Clarus in the United States District Court for the District of Delaware alleging that Clarus’s

JATENZO® product infringes six of Lipocine’s issued U.S.

However on February 11, 2020, we voluntarily dismissed allegations of patent infringement for expired U.S.

and 6,923,988 in an effort to streamline the issues and associated costs for dispute.

Clarus has answered the complaint

and asserted counterclaims of non-infringement and invalidity.

We answered Clarus’s counterclaims on April 29, 2019.

The Court held a scheduling conference on August 15, 2019, a claim construction hearing on February 11, 2020 and a summary judgment

hearing on January 15, 2021.

Originally the United States District Court for the District of Delaware had scheduled a five-day jury

trial to begin on February 8, 2021, however, on December 28, 2020, the District Court postponed the jury trial due to the ongoing

effects of the COVID-19 pandemic.

The jury trial will be rescheduled once it becomes clear when jury trials will resume in the District

On November 14, 2019, we and certain of our

officers were named as defendants in a purported shareholder class action lawsuit, Solomon Abady v.

Clarus has answered the complaint and asserted

counterclaims of non-infringement and invalidity.

We answered Clarus’s counterclaims on April 29, 2019.

The Court held a scheduling

conference on August 15, 2019, a claim construction hearing on February 11, 2020 and a summary judgment hearing on January 15, 2021.

In May 2021, the Court granted Clarus’ motion for Summary Judgment, finding the asserted claims of Lipocine’s U.S.

and 9,757,390 invalid for failure to satisfy the written description requirement of 35 U.S.C.

Clarus still had remaining claims before the Court.

On July 13, 2021, Clarus and Lipocine entered into a global settlement agreement

(“Global Agreement”) which resolved all outstanding claims of this litigation as well as the on-going United States Patent

and Trademark Office (“USPTO”) Interference No.

106,128 between the parties.

Under the terms of the Global Agreement, Lipocine

agreed to pay Clarus $4.0 million payable as follows:

$2.5 million immediately, $1.0 million on July 13, 2022 and $500,000 on July 13,

No future royalties are owing from either party.

On July 15, 2021, the Court dismissed with prejudice Lipocine’s claims and

Clarus’ counterclaims.

November 14, 2019, we and certain of our officers were named as defendants in a purported shareholder class action lawsuit, Solomon

Lipocine Inc.

et al ., 2:19-cv-00906-PMW,

filed in the United District Court for the District of Utah.

The complaint alleges that the defendants made false and/or misleading statements

and/or failed to disclose that our filing of the NDA for TLANDO to the FDA contained deficiencies and as a result the defendants’

statements about our business and operations were false and misleading and/or lacked a reasonable basis in violation of federal securities

The lawsuit seeks certification as a class action (for a purported class of purchasers of the Company’s securities from March 27,

2019 through November 8, 2019), compensatory damages in an unspecified amount, and unspecified equitable or injunctive relief.

have insurance that covers claims of this nature.

The retention amount payable by us under our policy is $1.25 million.

We filed a motion

to dismiss this class action lawsuit on July 24, 2020.

In response, the plaintiffs filed their response to the motion to dismiss

the class action lawsuit on September 22, 2020 and we filed our reply to our motion to dismiss on October 22, 2020.

to vigorously defend ourselves against these allegations and have not recorded a liability related to this shareholder class action lawsuit

as the outcome is not probable nor can an estimate be made of loss, if any.

On March 13, 2020, we filed U.S.

patent application serial number

16/818,779 (“the Lipocine ‘779 Application”) with the United States Patent and Trademark Office (“USPTO”).

et al ., 2:19-cv-00906-PMW, filed in the United District Court for the District of Utah.

The complaint alleges

that the defendants made false and/or misleading statements and/or failed to disclose that our filing of the NDA for TLANDO to the FDA

contained deficiencies and as a result the defendants’ statements about our business and operations were false and misleading and/or

lacked a reasonable basis in violation of federal securities laws.

The lawsuit seeks certification as a class action (for a purported

class of purchasers of the Company’s securities from March 27, 2019 through November 8, 2019), compensatory damages in an unspecified

amount, and unspecified equitable or injunctive relief.

We have insurance that covers claims of this nature.

The retention amount payable

by us under our policy is $1.25 million.

We filed a motion to dismiss this class action lawsuit on July 24, 2020.

In response, the plaintiffs

filed their response to the motion to dismiss the class action lawsuit on September 22, 2020 and we filed our reply to our motion to

dismiss on October 22, 2020.

We intend to vigorously defend ourselves against these allegations and have not recorded a liability related

to this shareholder class action lawsuit as the outcome is not probable nor can an estimate be made of loss, if any.

March 13, 2020, we filed U.S.

patent application serial number 16/818,779 (“the Lipocine ‘779 Application”) with the

On October 16 and November 3, 2020, we filed suggestions for interference with the USPTO requesting that a patent interference

be declared between the Lipocine ‘779 Application and US patent application serial number 16/656,178 to Clarus Therapeutics, Inc.

(“the Clarus ‘178 Application”).

Pursuant to our request, the Patent Trial and Appeal Board (“PTAB”)

at the USPTO declared the interference on January 4, 2021 to ultimately determine, as between us and Clarus, who is entitled to the

claimed subject matter.

be declared between the Lipocine ‘779 Application and US patent application serial number 16/656,178 to Clarus Therapeutics, Inc.

(“the Clarus ‘178 Application”).

Pursuant to our request, the Patent Trial and Appeal Board (“PTAB”) at

the USPTO declared the interference on January 4, 2021 to ultimately determine, as between us and Clarus, who is entitled to the claimed

subject matter.

The interference number is 106,128, and we were initially declared Senior Party.

A conference call

with the PTAB was held on January 25, 2021 to discuss proposed motions.

On February 1, 2021, the PTAB issued an order

authorizing certain motions and setting the schedule for the preliminary motions phase.

Briefing is presently ongoing.

A conference call with the PTAB was

held on January 25, 2021 to discuss proposed motions.

On February 1, 2021, the PTAB issued an order authorizing certain motions and setting

the schedule for the preliminary motions phase.

On July 13, 2021, we entered into the Global Agreement with Clarus to resolve interference

106,128 among other items.

On July 26, 2021, the PTAB granted our request for adverse judgment in interference No.

106,128 in accordance

with the Global Agreement.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 1. Legal Proceedings